{"protocolSection":{"identificationModule":{"nctId":"NCT03694392","orgStudyIdInfo":{"id":"CN-18-3176"},"organization":{"fullName":"Kaiser Permanente","class":"OTHER"},"briefTitle":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","officialTitle":"Examining Vaccine Effectiveness (VE) of Flublok Relative to Standard Dose Inactivated Influenza Vaccine Among Kaiser Permanente Northern California Members Aged 18-64 Years"},"statusModule":{"statusVerifiedDate":"2023-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-09-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-04-09","type":"ACTUAL"},"completionDateStruct":{"date":"2022-12-31","type":"ACTUAL"},"studyFirstSubmitDate":"2018-09-27","studyFirstSubmitQcDate":"2018-10-01","studyFirstPostDateStruct":{"date":"2018-10-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-02-27","lastUpdatePostDateStruct":{"date":"2023-03-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Kaiser Permanente","class":"OTHER"},"collaborators":[{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"}]},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age. During this study, Flublok Quadrivalent or SD-IIV will be administered according to the guidelines in the Prescribing Information materials and only to persons for whom it is indicated. The 2018-2019, 2019-2020, and 2020-2021 formulations of recombinant influenza vaccine (Flublok Quadrivalent vaccine) and SD-IIV will be evaluated for outcomes including all polymerase chain reaction (PCR)-confirmed influenza, PCR-confirmed hospitalized influenza, hospitalized community-acquired pneumonia and cardio-respiratory events."},"conditionsModule":{"conditions":["Influenza","Pneumonia","Lower Respiratory Tract Infection","Acute Myocardial Infarction","Congestive Heart Failure","Stroke"],"keywords":["influenza","vaccine effectiveness"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":2776278,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Flublok Recipients","description":"Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.","interventionNames":["Biological: Flublok Quadrivalent"]},{"label":"SD-IIV Recipients","description":"Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).","interventionNames":["Biological: Standard Dose Inactivated Influenza Vaccine (SD-IIV)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Flublok Quadrivalent","description":"Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.","armGroupLabels":["Flublok Recipients"]},{"type":"BIOLOGICAL","name":"Standard Dose Inactivated Influenza Vaccine (SD-IIV)","description":"For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.","armGroupLabels":["SD-IIV Recipients"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of adults 50-64 years old with polymerase-chain reaction (PCR) confirmed influenza tests","description":"Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had a PCR-confirmed positive influenza test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30).","timeFrame":"Up to 8 months"}],"secondaryOutcomes":[{"measure":"Number of adults 50-64 years old hospitalized with PCR-confirmed influenza","description":"Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay and had a PCR-confirmed positive influenza test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30).","timeFrame":"Up to 8 months"},{"measure":"Number of adults 50-64 years old hospitalized with community-acquired pneumonia","description":"Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay for community-acquired pneumonia (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30).","timeFrame":"Up to 8 months"},{"measure":"Number of adults 50-64 years old hospitalized with cardio-respiratory events","description":"Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay for cardio-respiratory events (e.g., pneumonia, other lower respiratory infections, acute myocardial infarction, congestive heart failure, stroke) (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30).","timeFrame":"Up to 8 months"}],"otherOutcomes":[{"measure":"Number of adults 50-64 years old with select exploratory outcomes","description":"Patients who receive either Flublok or SD-IIV will be retroactively assessed (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30) for:\n\n1. PCR-tested with an influenza-like illness (ILI) International Classification of Diseases, 10th Edition code\n2. All-cause hospitalizations\n3. All-cause mortality\n4. Cardiovascular events (e.g., acute myocardial infarction, congestive heart failure, stroke, atrial fibrillation)","timeFrame":"Up to 8 months"},{"measure":"Outcomes 1-4 to be assessed for adults 18-64 years old","description":"Patients who receive either Flublok or SD-IIV will be retroactively assessed for outcomes 1-4 described (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30).","timeFrame":"Up to 8 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Between the ages of ≥18 and \\<65 years at the time of influenza vaccination\n* Receive either Flublok Quadrivalent vaccine or standard dose inactivated influenza vaccine at a Kaiser Permanente Northern California facility during the study period from August 2018 through April 2020\n\nExclusion Criteria:\n\n* Children \\<18 years old\n* Adults ≥65 years old","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"],"studyPopulation":"Eligible adults aged 18-64 years will receive either Flublok Quadrivalent vaccine or a standard dose inactivated influenza vaccine in the course of routine influenza vaccination during each of the two influenza seasons of the study period at Kaiser Permanente Northern California.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Nicola P Klein, MD, PhD","affiliation":"Kaiser Permanente","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Kaiser Permanente Northern California (entire region)","city":"Oakland","state":"California","zip":"94612","country":"United States","geoPoint":{"lat":37.80437,"lon":-122.2708}}]},"referencesModule":{"references":[{"pmid":"34998605","type":"DERIVED","citation":"Hsiao A, Hansen J, Nunley KV, Lewis N, Selmani A, Inamdar A, Mallett-Moore T, Izikson R, Rudin D, Klein NP. Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study. Vaccine. 2022 Jan 31;40(5):774-779. doi: 10.1016/j.vaccine.2021.12.035. Epub 2022 Jan 6."}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"All data reported to Sanofi Pasteur by the Kaiser Permanente Northern California Vaccine Study Center will be deidentified and aggregated."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000007251","term":"Influenza, Human"},{"id":"D000012141","term":"Respiratory Tract Infections"},{"id":"D000006333","term":"Heart Failure"},{"id":"D000009203","term":"Myocardial Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000007239","term":"Infections"},{"id":"D000009976","term":"Orthomyxoviridae Infections"},{"id":"D000012327","term":"RNA Virus Infections"},{"id":"D000014777","term":"Virus Diseases"},{"id":"D000012140","term":"Respiratory Tract Diseases"},{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000014652","term":"Vascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9985","name":"Influenza, Human","asFound":"Influenza","relevance":"HIGH"},{"id":"M9111","name":"Heart Failure","asFound":"Congestive Heart Failure","relevance":"HIGH"},{"id":"M9973","name":"Infections","relevance":"LOW"},{"id":"M13594","name":"Pneumonia","relevance":"LOW"},{"id":"M6058","name":"Communicable Diseases","relevance":"LOW"},{"id":"M11845","name":"Myocardial Infarction","asFound":"Myocardial Infarction","relevance":"HIGH"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M14668","name":"Respiratory Tract Infections","asFound":"Respiratory Tract Infections","relevance":"HIGH"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M12592","name":"Orthomyxoviridae Infections","relevance":"LOW"},{"id":"M17212","name":"Virus Diseases","relevance":"LOW"},{"id":"M14839","name":"RNA Virus Infections","relevance":"LOW"},{"id":"M14667","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","relevance":"LOW"},{"id":"M19196","name":"Myocardial Ischemia","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC01","name":"Infections"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M17050","name":"Vaccines","relevance":"LOW"},{"id":"M9166","name":"Hemagglutinins","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Coag","name":"Coagulants"}]}},"hasResults":false}